Patent Examiner Lauren Quinlan Wells
Art Unit 1622 · Small-Molecule Drugs, Treatment Methods & Organic Synthesis · Tech Center 1600 · 344 applications filed 2021–2026
Lauren Quinlan Wells is a USPTO patent examiner in Art Unit 1622 (Small-Molecule Drugs, Treatment Methods & Organic Synthesis) with 344 applications from filing years 2021–2026. Examiner Wells's allowance rate is 47.2%, below the 82.2% USPTO average for applications filed in the same years. The examiner ranks harder than 91% of examiners. In 2021, decided applications with an examiner interview were allowed 71.8 percentage points more often than those without.
Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology
Overview
FreeExaminer details
- Art unit1622 · Small-Molecule Drugs, Treatment Methods & Organic Synthesis
- Title / gradePatent Examiner · GS-13
- Service5 years
- PhoneOn each office action
- In USPTO recordsWELLS, LAUREN QUINLAN
How to improve your odds with Examiner Wells
- The data favors an interview. Interviewed cases were allowed more often in all 4 measured years, by 31.6 to 79.4 points.
- Plan for the timeline. First office action averages 670 days vs the 608-day USPTO norm.
- Expect a §103. Obviousness is the most-issued rejection (299), and applicants overcame it 32.5% of the time.
- The data favors an RCE here. Cases with an RCE were allowed more often in all 4 measured years, by 16.6 to 33.3 points.
Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.
Rejection patterns & how they get overcome
FreeApplicants overcame 67 of the 206 decided §103 obviousness rejections from Examiner Wells in the data. Each winning response, with its arguments and claim amendments, is in the file wrapper.
Just got an office action from Examiner Wells?
Draft your response with Examiner Wells's record and Art Unit 1622's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See how Boundly assists with office action responses.
Trends
| Year | Interview rate | Allowance w/ interview | Allowance w/o | Delta |
|---|---|---|---|---|
| 2024 | 22.5% | 91.7% | 33.3% | +58.4pp |
| 2023 | 39.2% | 95.2% | 15.8% | +79.4pp |
| 2022 | 36.7% | 63.2% | 31.6% | +31.6pp |
| 2021 | 40.0% | 81.6% | 9.8% | +71.8pp |
RCE behavior
Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Wells.
| Year | RCE rate | Allowance w/ RCE | Allowance w/o | Delta |
|---|---|---|---|---|
| 2024 | 13.8% | 83.3% | 66.7% | +16.6pp |
| 2023 | 29.7% | 80.0% | 50.0% | +30.0pp |
| 2022 | 45.0% | 64.3% | 37.5% | +26.8pp |
| 2021 | 41.9% | 57.9% | 24.6% | +33.3pp |
Recent outcomes
Free🔒 Case detail for members| App # | Title | Outcome | OAs | Arguments & redline |
|---|---|---|---|---|
| 18/252843 | Substances for Treatment of Hyperuricaemia | Patented | 1 | 🔒 View |
| 18/024831 | Composition Comprising Cannabinoids, and/or Terpens, and Methods of Using Same | Patented | 2 | 🔒 View |
| 18/044964 | Methods of Treating Symptoms of Coronavirus Infection | Abandoned | 2 | 🔒 View |
| 17/978442 | Neutral Endopeptidase (NEP) and Human Soluble Endopeptidase (hSEP) Inhibitors for Prophylaxis and Treatment of Eye Diseases | Patented | 6 | 🔒 View |
Art Unit 1622 technology
Frequently asked questions
What is Examiner Lauren Quinlan Wells's allowance rate?
Is Examiner Wells a hard examiner?
Do examiner interviews help with Examiner Wells?
What is Examiner Wells's most common rejection?
Is an RCE worth filing with Examiner Wells?
How long until the first office action from Examiner Wells?
Put Examiner Wells's data to work on your next response.
Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.